Nasdaq · Biotech stocks database
OPTH — Optimi Health Corp. ☆
OPTH (Optimi Health Corp.) stock: $2.34, $13.4M market cap, $9.2M cash, $4.2M EV. Data from Fully Diluted's biotech stocks database.
Overview
Catalysts
Assets
Pipeline
Trials
Holders
News
What they do
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of LYTENAVA (bevacizumab-vikg), the only FDA-approved ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration, which the company launched commercially in 2026.
Source: company website via company website
Balance sheet
Cash $9.2M Debt $0.0M Net cash $9.2M Enterprise value $4.2M Basic shares 5.7M shares Fully diluted shares Not disclosed Fully diluted market cap Not disclosed Cash per share $1.60
Cash figures as of 2026-09-16. Database snapshot: 2026-11-07.
Share structure
Cap table as of 2026-09-16.
Price history Loading OPTH daily closes…
Loading price history…
Asset data not yet available for this company.
No lead program on file for this company.
No active ClinicalTrials.gov trials matched to this company as sponsor or collaborator.
Specialist fund holders Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
None of the tracked specialist funds reported a position in the latest 13F snapshot.
Fully Diluted · Free biotech stocks database. Figures are sourced from SEC filings and company disclosures; not investment advice.